Medications

Mylan, like other generic drugmakers, feels the pricing pain

Mylan's second-quarter profit and revenue surged, but not as much as Wall Street had expected and the company is taking a more conservative view going forward because of "ongoing challenges and the uncertain U.S. regulatory ...

Health

Pro-pot arguments fly higher with likely voters

Four states legalized recreational marijuana in November, nearly doubling the number of states where recreational pot is legal. As more states consider joining them, a range of arguments for and against legalization is swirling ...

Medications

Novartis profit slips as key drug goes generic

Swiss drug company Novartis saw net profit slip in the third quarter as the loss of a key drug to generic use in the United States outweighed strong sales of its psoriasis drug Cosentyx and MS treatment Gilenya.

Medications

Slight increase in Norwegian drug consumption in 2015

Drug sales measured in defined daily doses (DDD) increased by 2 per cent from 2014 to 2015. Revenue growth was 8.6 per cent. This is shown in "Drug Consumption in Norway 2011-2015", a report issued by the Norwegian Institute ...

page 5 from 9